Literature DB >> 8264332

Potential involvement of the transcription factor NF-kappa B in neurological disorders.

B Kaltschmidt1, P A Baeuerle, C Kaltschmidt.   

Abstract

Reactive oxygen intermediates (ROIs) are involved in many neurological diseases. Despite the toxic nature of these compounds, low concentrations of ROIs can function as signaling molecules. One target for their signaling function is the inducible transcription factor NF-kappa B. Predominantly in lymphoid cells, induction of NF-kappa B in response to oxidative stress leads to transcriptional activation of many genes which are relevant for pathogen defense. These include the TNF, IL-6, IL-8, GM-CSF, beta-interferon, MHC class I and V-CAM genes. However, NF-kappa B is also abundant in various cell types of the nervous system, including neurons. We propose that NF-kappa B plays a role as a redox-controlled transcriptional activator also in cells of the nervous system and in that property may contribute to neurological disorders. Our finding that some neurons from healthy brain contain constitutively active NF-kappa B suggests a role of NF-kappa B in normal brain function as well.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8264332     DOI: 10.1016/0098-2997(93)90004-w

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  27 in total

1.  NF-kappa B signaling promotes both cell survival and neurite process formation in nerve growth factor-stimulated PC12 cells.

Authors:  E D Foehr; X Lin; A O'Mahony; R Geleziunas; R A Bradshaw; W C Greene
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  CREB and NF-kappaB transcription factors regulate sensitivity to excitotoxic and oxidative stress induced neuronal cell death.

Authors:  Jian Zou; Fulton Crews
Journal:  Cell Mol Neurobiol       Date:  2006-04-22       Impact factor: 5.046

3.  Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaBbeta degradation.

Authors:  J L Cheshire; A S Baldwin
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

Review 4.  Methylmercury: recent advances in the understanding of its neurotoxicity.

Authors:  Michael Aschner; Tore Syversen
Journal:  Ther Drug Monit       Date:  2005-06       Impact factor: 3.681

Review 5.  Prolyl 4-hydroxylase activity-responsive transcription factors: from hydroxylation to gene expression and neuroprotection.

Authors:  Ambreena Siddiq; Leila R Aminova; Rajiv R Ratan
Journal:  Front Biosci       Date:  2008-01-01

Review 6.  Tachykinin peptide, substance P, and its receptor NK-1R play an important role in alimentary tract mucosal inflammation during cytotoxic therapy.

Authors:  P S Satheeshkumar; Minu P Mohan
Journal:  Dig Dis Sci       Date:  2014-07-01       Impact factor: 3.199

7.  Skeletal muscle expression of bone morphogenetic protein-1 and tolloid-like-1 extracellular proteases in different fiber types and in response to unloading, food deprivation and differentiation.

Authors:  David L Allen; Bradley J Greybeck; Bradley J Greyback; Andrea M Hanson; Allison S Cleary; Sarah F Lindsay
Journal:  J Physiol Sci       Date:  2010-07-24       Impact factor: 2.781

8.  Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation.

Authors:  Salvatore Cuzzocrea; Prabal K Chatterjee; Emanuela Mazzon; Laura Dugo; Ivana Serraino; Domenico Britti; Giuseppe Mazzullo; Achille P Caputi; Christoph Thiemermann
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

9.  Traumatic spinal cord injury induces nuclear factor-kappaB activation.

Authors:  J R Bethea; M Castro; R W Keane; T T Lee; W D Dietrich; R P Yezierski
Journal:  J Neurosci       Date:  1998-05-01       Impact factor: 6.167

10.  Constitutive nuclear factor-kappa B activity is required for central neuron survival.

Authors:  Asha L Bhakar; Laura-Lee Tannis; Christine Zeindler; Maria Pia Russo; Christian Jobin; David S Park; Sandra MacPherson; Philip A Barker
Journal:  J Neurosci       Date:  2002-10-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.